Silo Pharma, Inc. (SILO) income statement
SILONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.71−0.17 (-9.04%)
Close on Nov 20, 2026Market cap $2.72MP/E –Yield –
Silo Pharma, Inc. financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $2.72MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||||||||
| Gross margin | 38.6% | 91.9% | 91.9% | 91.9% | – | -330.4% | 32.5% | – | – | – | – | – | – | – |
| Operating margin | -5,937.0% | -6,526.4% | -5,347.4% | -5,031.3% | – | -5,380.2% | -2,293.4% | – | – | – | – | – | – | – |
| Pre-tax margin | -5,863.5% | -6,092.6% | -5,036.0% | -5,419.3% | – | -6,515.3% | – | – | – | – | – | – | – | – |
| Net profit margin | -5,863.5% | -6,092.6% | -5,132.6% | -5,420.9% | – | -7,422.5% | -2,497.7% | – | – | – | – | – | – | – |
| Effective tax rate | – | – | – | – | 0.59% | – | – | – | – | – | – | – | – | – |
| Returns on capital | ||||||||||||||
| Return on equity | -74.6% | -78.4% | -44.8% | -40.3% | 48.3% | -483.0% | -527.0% | -120.4% | 34.8% | – | – | 183.7% | -217.8% | – |
| Return on assets | -56.3% | -58.0% | -38.2% | -35.3% | 65.5% | -316.3% | -150.2% | -77.7% | 21.7% | – | – | -3,884.4% | -202.3% | – |
| Return on tangible assets | -58.0% | -59.9% | -38.2% | -35.3% | 65.5% | -316.3% | -150.2% | -79.5% | 21.7% | – | – | -3,884.4% | -202.3% | – |
| Return on invested capital | – | – | – | – | – | -1,111.0% | – | – | – | – | – | – | – | – |
| Return on capital employed | -67.4% | -74.0% | -42.4% | -34.2% | -48.6% | -264.9% | -157.1% | -49.3% | -30.6% | – | – | – | – | – |
| Return on total capital | – | – | – | – | – | -171.3% | – | – | – | – | – | – | – | – |
| NOPAT | -$3.38M | -$3.72M | -$3.05M | -$2.87M | -$2.73M | -$1.74M | -$735.02K | -$469.45K | -$387.79K | – | – | – | – | – |
| Cash flow quality | ||||||||||||||
| OCF / Sales | -6,464.9% | -5,317.3% | -4,472.1% | -4,850.9% | – | -2,827.3% | -1,958.0% | – | – | – | – | – | – | – |
| OCF / Net income | 1.10 | 0.87 | 0.87 | 0.89 | -0.58 | 0.38 | 0.78 | -0.28 | -0.80 | – | – | 0.54 | 0.93 | – |
| Efficiency | ||||||||||||||
| Asset turnover | 0.01 | 0.01 | 0.01 | 0.01 | – | 0.04 | 0.06 | – | – | – | – | – | – | – |
| Receivables turnover | – | – | – | 1.09 | – | 1.74 | – | – | – | – | – | – | – | – |
| Days sales outstanding | – | – | – | 334.2 | – | 209.6 | – | – | – | – | – | – | – | – |
| Payables turnover | 0.04 | 0.01 | 0.01 | 0.01 | 0.02 | 1.94 | 0.68 | – | – | – | – | – | – | – |
| Days payables outstanding | 8,907.6 | 71,505.2 | 33,377.2 | 24,450.7 | 19,876.8 | 188.5 | 536.4 | – | – | – | – | – | – | – |
| Inventory turnover | – | – | – | – | – | 1.86 | 0.30 | – | – | – | – | – | – | – |
| Days inventory outstanding | – | – | – | – | – | 196.7 | 1,221.7 | – | – | – | – | – | – | – |
| Operating cycle | – | – | – | – | – | 406.3 | – | – | – | – | – | – | – | – |
| Cash conversion cycle | – | – | – | – | – | 217.8 | – | – | – | – | – | – | – | – |
| Liquidity | ||||||||||||||
| Current ratio | 11.36 | 4.29 | 9.90 | 26.52 | 21.23 | 10.07 | 4.23 | 13.05 | 42.81 | – | – | 0.01 | 0.50 | – |
| Quick ratio | 11.36 | 4.29 | 9.90 | 26.52 | 21.23 | 9.83 | 2.89 | 12.49 | 42.81 | – | – | 0.01 | 0.50 | – |
| Cash ratio | 10.55 | 4.28 | 9.88 | 26.05 | 20.07 | 7.96 | 0.96 | 7.02 | 7.68 | – | – | 0.01 | 0.50 | – |
| Working capital | $6.74M | $5.46M | $6.91M | $11.14M | $9.91M | $1.28M | $377.11K | $578.00K | $1.60M | – | – | -$25.41K | -$1.75K | $47.48K |
| Net current asset value | $6.09M | $4.73M | $6.11M | $10.27M | $8.97M | $1.28M | $377.11K | $178.00K | $1.20M | – | – | -$41.19K | -$1.75K | $47.48K |
| Leverage | ||||||||||||||
| Total debt | – | – | – | – | – | $4.25K | – | – | – | – | – | $15.00K | $0 | – |
| Net debt | – | – | – | – | – | -$1.12M | – | – | – | – | – | $14.72K | -$1.75K | – |
| Debt / Equity | – | – | – | – | – | 0.00 | – | – | – | – | – | -0.36 | -0.00 | – |
| Debt ratio | – | – | – | – | – | 0.30% | – | – | – | – | – | 5,376.3% | 0.00% | – |
| Assets to equity | 1.21 | 1.47 | 1.25 | 1.13 | 1.16 | 1.11 | -21.57 | 2.10 | 1.36 | – | 1.23 | -0.01 | -1.00 | 1.00 |
| Long-term debt to assets | – | – | – | – | – | 0.30% | – | – | – | – | – | 5,376.3% | 0.00% | – |
| Long-term debt to equity | – | – | – | – | – | 0.00 | – | – | – | – | – | -0.36 | -0.00 | – |
| Total debt / Capitalization | – | – | – | – | – | 0.33% | – | – | – | – | – | -57.3% | -0.00% | – |
| Long-term debt / Capitalization | – | – | – | – | – | 0.33% | – | – | – | – | – | -57.3% | -0.00% | – |
| Cash flow to debt | – | – | – | – | – | -27,249.1% | – | – | – | – | – | -143.2% | – | – |
| Intangibles to total assets | 2.9% | 3.3% | – | – | – | – | – | 3.4% | – | – | – | – | – | – |
| Interest coverage | ||||||||||||||
| EBIT / Interest expense | -114.76 | -925.59 | -791.87 | -1,649.68 | -903.93 | -27,521.49 | – | – | – | – | – | – | – | – |
| Per share | ||||||||||||||
| Revenue per share | 0.08 | 0.24 | 0.37 | 0.34 | – | 0.36 | 1.29 | – | – | – | – | – | – | – |
| EPS (basic) | -7.50 | -17.85 | -18.00 | – | 30.00 | -37.50 | -30.00 | -15.00 | 7.50 | – | – | 0.00 | 0.00 | – |
| EPS (diluted) | -7.50 | -17.85 | -18.00 | – | 30.00 | -37.50 | -30.00 | -15.00 | 7.50 | – | – | 0.00 | 0.00 | – |
| Book value per share | 7.10 | 16.84 | 31.88 | 49.10 | 68.91 | 11.28 | -0.73 | 13.05 | 18.02 | – | 25.65 | -1.01 | -0.04 | 1.16 |
| Tangible book value per share | 6.86 | 16.03 | 31.88 | 49.10 | 68.91 | 11.28 | -0.73 | 12.11 | 18.02 | – | 25.65 | -1.01 | -0.04 | 1.16 |
| Cash per share | 7.72 | 23.68 | 39.56 | 53.98 | 74.80 | 9.94 | 3.55 | 10.78 | 4.41 | – | 37.14 | 0.0068 | 0.04 | 1.16 |
| Operating cash flow per share | -5.25 | -12.82 | -16.64 | -16.61 | -17.32 | -10.19 | -25.24 | 8.73 | -4.26 | – | -3.35 | -0.53 | -1.13 | – |
| Valuation at period end | ||||||||||||||
| Market cap | $3.56M | $3.99M | $4.48M | $10.55M | $14.06M | $36.13M | – | – | – | – | – | – | – | – |
| Enterprise value | -$2.31M | -$4.02M | -$4.29M | -$1.71M | $3.79M | $34.49M | – | – | – | – | – | – | – | – |
| P/E | – | – | – | – | 3.6x | – | – | – | – | – | – | – | – | – |
| P/S | 49.3x | 55.4x | 62.1x | 146x | – | 883x | – | – | – | – | – | – | – | – |
| P/B | 0.6x | 0.8x | 0.7x | 1.0x | 1.6x | 28.2x | – | – | – | – | – | – | – | – |
| P/TBV | 0.6x | 0.8x | 0.7x | 1.0x | 1.6x | 28.2x | – | – | – | – | – | – | – | – |
| P/Gross profit | 128x | 60.2x | 67.6x | 159x | 212x | -267x | – | – | – | – | – | – | – | – |
| P/OCF | -0.8x | -1.0x | -1.4x | -3.0x | -6.2x | -31.2x | – | – | – | – | – | – | – | – |
| EV/Sales | -32.0x | -55.8x | -59.6x | -23.7x | – | 843x | – | – | – | – | – | – | – | – |
| EV/Gross profit | -83.1x | -60.7x | -64.8x | -25.8x | 57.3x | -255x | – | – | – | – | – | – | – | – |
| EV/EBIT | 0.5x | 0.9x | 1.1x | 0.5x | – | – | – | – | – | – | – | – | – | – |
| EV/OCF | 0.5x | 1.0x | 1.3x | 0.5x | -1.7x | -29.8x | – | – | – | – | – | – | – | – |
| Earnings yield | -118.9% | -110.1% | -82.7% | -37.1% | 27.8% | -8.4% | – | – | – | – | – | – | – | – |
| Cost structure | ||||||||||||||
| R&D to revenue | 2,996.9% | 3,284.5% | 1,172.1% | 1,784.2% | – | 64.1% | – | – | – | – | – | – | – | – |
| SG&A to revenue | – | – | 541.0% | 315.2% | – | 122.6% | – | – | – | – | – | – | – | – |
| Stock-based comp to revenue | 162.3% | 0.00% | 1,208.9% | 801.2% | – | 1,847.4% | 787.8% | – | – | – | – | – | – | – |
| Per employee | ||||||||||||||
| Total employees | 3 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Revenue per employee | $24.03K | $24.03K | $24.03K | $24.03K | – | $40.92K | $40.57K | – | – | – | – | – | – | – |
| Gross profit per employee | $9.27K | $22.09K | $22.09K | $22.09K | $33.13K | -$135.20K | $13.18K | – | – | – | – | – | – | – |
| Operating profit per employee | -$1.43M | -$1.57M | -$1.29M | -$1.21M | -$1.37M | -$2.20M | -$930.40K | -$594.24K | -$490.87K | – | – | – | – | – |
| Net income per employee | -$1.41M | -$1.46M | -$1.23M | -$1.30M | $1.95M | -$3.04M | -$1.01M | -$969.46K | $356.54K | – | – | -$39.45K | -$49.80K | – |
| Growth | ||||||||||||||
| Revenue 1Y growth | 0.00% | 0.00% | 0.00% | – | – | 0.87% | – | – | – | – | – | – | – | – |
| Revenue 3Y CAGR | 0.00% | – | 20.8% | 21.1% | – | – | – | – | – | – | – | – | – | – |
| Revenue 5Y CAGR | 12.0% | 12.2% | – | – | – | – | – | – | – | – | – | – | – | – |
| Gross profit 1Y growth | -58.0% | 0.00% | 0.00% | 0.01% | 149.0% | -1,125.7% | – | – | – | – | – | – | – | – |
| Gross profit 3Y CAGR | -25.1% | 0.00% | – | 71.3% | – | – | – | – | – | – | – | – | – | – |
| Gross profit 5Y CAGR | – | 38.1% | – | – | – | – | – | – | – | – | – | – | – | – |
| EBIT 1Y growth | 9.0% | -22.0% | -6.3% | -32.2% | -24.6% | -136.6% | -56.6% | -21.1% | – | – | – | – | – | – |
| Net income 1Y growth | 3.8% | -18.7% | 5.3% | -200.1% | 228.5% | -199.8% | -4.5% | -371.9% | – | – | – | 20.8% | – | – |
| Diluted EPS 1Y growth | 58.0% | 0.83% | – | – | 180.0% | -25.0% | -100.0% | -300.0% | – | – | – | – | – | – |
| Operating cash flow 1Y growth | -21.6% | -18.9% | 7.8% | -53.5% | -96.9% | -45.7% | -391.3% | 195.8% | – | – | -745.8% | 53.6% | – | – |
| Total assets 1Y growth | 2.6% | -4.3% | -33.5% | 11.0% | 635.3% | 188.9% | -42.3% | -47.9% | – | – | 791,077.1% | -84.1% | -96.3% | – |
| Total assets 3Y CAGR | -13.2% | -10.9% | 75.8% | 186.7% | 130.6% | -4.6% | – | – | – | – | 259.6% | – | – | – |
| Total assets 5Y CAGR | 39.8% | 71.9% | 55.4% | 48.0% | – | – | – | -17.3% | 467.4% | – | – | – | – | – |
| Total assets 10Y CAGR | – | – | 13.4% | 189.8% | 138.6% | 40.5% | – | – | – | – | – | – | – | – |
| Total equity 1Y growth | 25.3% | -18.5% | -40.3% | 14.1% | 607.6% | 5,694.5% | -105.6% | -66.1% | 42.1% | – | 4,442.1% | -2,256.6% | -103.7% | – |
| Total equity 3Y CAGR | -15.2% | -17.8% | 69.0% | – | 181.2% | 2.1% | – | – | – | -22.1% | 235.2% | – | – | – |
| Total equity 5Y CAGR | 37.5% | – | 72.2% | 53.8% | 60.7% | – | – | -25.6% | – | – | – | – | – | – |
| Total equity 10Y CAGR | – | – | 13.2% | – | – | 39.0% | – | – | – | – | – | – | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.